Comparative efficacy and safety of NALIRIFOX versus other first-line chemotherapy regimens in metastatic pancreatic ductal adenocarcinoma: a retrospective study
Yuqi Wang, Jiayi Liu, Jiaxin Wang, Xiaoli Liu, Jingxin Zhang, Dawei Chen · 2026
Read Comparative efficacy and safety of NALIRIFOX versus other first-line chemotherapy regimens in metastatic pancreatic ductal adenocarcinoma: a retrospective study by Yuqi Wang, Jiayi Liu, Jiaxin Wang, Xiaoli Liu, Jingxin Zhang, Dawei Chen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13199695.txt.
Description
Yuqi Wang and colleagues compared first-line chemotherapy blends for spread pancreatic cancer in a 2026 records study. Three blends are all guideline-backed, yet which works best in daily practice was unsettled. The team reviewed patients treated at one center over about eighteen months.
They covered 215 patients across three regimens. NALIRIFOX, a four-drug blend, showed the best profile: longest time before growth, at a median of nine months, plus the highest response and disease-control rates. Overall survival had not yet split clearly between groups. Adjusted math still favored NALIRIFOX and a second blend over the third. Side effects were mostly mild, with no treatment deaths. Alcohol use independently tied to poorer survival.
Catalog record
| CREATOR | Yuqi Wang, Jiayi Liu, Jiaxin Wang, Xiaoli Liu, Jingxin Zhang, Dawei Chen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |